2026-01-24 - Analysis Report
**AbbVie (ABBV) Report**
==========================

**1. Company Overview**
AbbVie is a global biopharmaceutical company that discovers, develops, and delivers innovative therapies to treat diseases.

**2. Return Rate Comparison**
--------------------------------

* **Review Stock (ABBV):** Cumulative return of 179.45%
* **Comparison Stock (S&P 500, VOO):** Cumulative return of 126.41%
* **Divergence:** 53.00 (current), 67.90% (relative)

**3. Alpha, Beta Analysis**
----------------------------

| Year      | CAGR | MDD  | Alpha | Beta | Cap(B) |
|-----------|------|------|-------|------|--------|
| 2016-2018 | 38.0% | 23.2% | 26.0% | 1.0 | 162.9B |
| 2017-2019 | 27.0% | 23.2% | 2.0% | 1.1 | 156.5B |
| 2018-2020 | -18.0% | 33.0% | -42.0% | 0.8 | 189.4B |
| 2019-2021 | 79.0% | 33.0% | 13.0% | 0.7 | 239.3B |
| 2020-2022 | 104.0% | 33.0% | 97.0% | 0.6 | 285.6B |
| 2021-2023 | 57.0% | 19.7% | 36.0% | 0.4 | 273.9B |
| 2022-2024 | 34.0% | 19.7% | 4.0% | 0.3 | 314.1B |
| 2023-2025 | 84.0% | 20.4% | 8.0% | 0.3 | 403.8B |

**4. Recent Stock Price Fluctuations**
---------------------------------------

* **5-day SMA:** $216.38
* **20-day SMA:** $223.07
* **60-day SMA:** $225.05
* **Last-Market Price:** $219.26
* **Change:** $0.53 (+0.24%)

**5. RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence, Expected_Return**
----------------------------------------------------------------------------------------

* **Market Risk Indicator (MRI):** 0.70 (Medium Investment)
* **RSI:** 40.08
* **PPO:** -0.25
* **Hybrid Signal:** Buy (Cash 0%)
* **Risk Level:** Medium
* **Recent (20 days) relative divergence change:** +5.30 (improving)
* **7-day Rank change:** +9 (rank up)
* **7-day Dynamic Expected Return change:** -14.00% (worsening)
* **Expected Return (%):** 26.20%

**6. Recent News & Significant Events**
------------------------------------------

* [2026-01-02] What to Expect From AbbVie's Next Quarterly Earnings Report - Yahoo Finance (news.google.com)
* [2026-01-12] 3 No-Brainer Dividend Stocks to Buy Right Now - The Motley Fool (news.google.com)
* [2026-01-23] Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Epcoritamab Lymphoma Results - simplywall.st (news.google.com)
* [2026-01-23] AbbVie Inc. $ABBV Shares Purchased by Strs Ohio - MarketBeat (news.google.com)
* [2026-01-22] March 6th Options Now Available For AbbVie (ABBV) - Nasdaq (news.google.com)
* [2026-01-20] Lobbying Update: $1,330,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative (news.google.com)

**7. Analyst Opinions**
-------------------------

* **Analyst Consensus:**
 - Key: Buy
 - Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
 - Opinions: 27
 - Target Price (avg/high/low): 245.22 / 289.00 / 184.00

**8. Comprehensive Analysis (Summary of Previous Items, including News)**
--------------------------------------------------------------------------------

Based on the provided data, AbbVie (ABBV) has shown a strong return rate of 179.45%, outperforming the S&P 500 by 53.00 points and 67.90% relative to its past maximum-minimum fluctuation range. The Alpha, Beta analysis indicates a mix of high-growth and stable periods.

Recent stock price fluctuations indicate a slight increase of $0.53 (+0.24%) over the last market day. The 5-day, 20-day, and 60-day moving averages are $216.38, $223.07, and $225.05, respectively.

The RSI, PPO index indicators, and Delta_Previous_Relative_Divergence, Expected_Return suggest a medium-risk investment with a recent improvement in relative divergence. The expected return is 26.20%.

Recent news highlights AbbVie's positive phase 3 Epcoritamab lymphoma results, which may influence the company's valuation. Analyst opinions suggest a buy recommendation with a target price of 245.22.

Overall, AbbVie (ABBV) appears to be a strong stock with consistent growth, but its high-risk investment profile may deter some investors.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.